Increased activation product of complement 4 protein in plasma of individuals with schizophrenia
Agnieszka Kalinowski, Joanna Liliental, Lauren A Anker, Omer Linkovski, Collin Culbertson, Jacob N Hall, Reenal Pattni, Chiara Sabatti, Douglas Noordsy, Joachim F Hallmayer, Elizabeth D Mellins, Jacob S Ballon, Ruth O'Hara, Douglas F Levinson, Alexander E Urban, Agnieszka Kalinowski, Joanna Liliental, Lauren A Anker, Omer Linkovski, Collin Culbertson, Jacob N Hall, Reenal Pattni, Chiara Sabatti, Douglas Noordsy, Joachim F Hallmayer, Elizabeth D Mellins, Jacob S Ballon, Ruth O'Hara, Douglas F Levinson, Alexander E Urban
Abstract
Structural variation in the complement 4 gene (C4) confers genetic risk for schizophrenia. The variation includes numbers of the increased C4A copy number, which predicts increased C4A mRNA expression. C4-anaphylatoxin (C4-ana) is a C4 protein fragment released upon C4 protein activation that has the potential to change the blood-brain barrier (BBB). We hypothesized that elevated plasma levels of C4-ana occur in individuals with schizophrenia (iSCZ). Blood was collected from 15 iSCZ with illness duration < 5 years and from 14 healthy controls (HC). Plasma C4-ana was measured by radioimmunoassay. Other complement activation products C3-ana, C5-ana, and terminal complement complex (TCC) were also measured. Digital-droplet PCR was used to determine C4 gene structural variation state. Recombinant C4-ana was added to primary brain endothelial cells (BEC) and permeability was measured in vitro. C4-ana concentration was elevated in plasma from iSCZ compared to HC (mean = 654 ± 16 ng/mL, 557 ± 94 respectively, p = 0.01). The patients also carried more copies of the C4AL gene and demonstrated a positive correlation between plasma C4-ana concentrations and C4A gene copy number. Furthermore, C4-ana increased the permeability of a monolayer of BEC in vitro. Our findings are consistent with a specific role for C4A protein in schizophrenia and raise the possibility that its activation product, C4-ana, increases BBB permeability. Exploratory analyses suggest the novel hypothesis that the relationship between C4-ana levels and C4A gene copy number could also be altered in iSCZ, suggesting an interaction with unknown genetic and/or environmental risk factors.
Conflict of interest statement
Dr. Jacob Hall receives speaker fees from Biogen. The remaining authors declare no competing interests.
© 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.
Figures
References
- Gorelik A, Sapir T, Haffner-Krausz R, Olender T, Woodruff TM, Reiner O. Developmental activities of the complement pathway in migrating neurons. Nat Commun. 2017;8:1–12. doi: 10.1038/ncomms15096.
- Mayilyan KR, Weinberger DR, Sim RB. The complement system in schizophrenia. Drug News Perspect. 2008;21:200–10. doi: 10.1358/dnp.2008.21.4.1213349.
- Woo JJ, Pouget JG, Zai CC, Kennedy JL. The complement system in schizophrenia: where are we now and what’s next? Mol Psychiatry. 2020;25:114–30. doi: 10.1038/s41380-019-0479-0.
- Magdalon J, Mansur F, Teles E Silva AL, de Goes VA, Reiner O, Sertié AL. Complement system in brain architecture and neurodevelopmental disorders. Front Neurosci. 2020;14:1–14. doi: 10.3389/fnins.2020.00023.
- Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science. 2018;362:eaat8127. doi: 10.1126/science.aat8127.
- Rey R, Suaud-Chagny MF, Bohec AL, Dorey JM, d'Amato T, Tamouza R, et al. Overexpression of complement component C4 in the dorsolateral prefrontal cortex, parietal cortex, superior temporal gyrus and associative striatum of patients with schizophrenia. Brain Behav Immun. 2020;90:216–25. doi: 10.1016/j.bbi.2020.08.019.
- Sekar A, Bialas AR, de Rivera H, Davis A, Hammond TR, Kamitaki N, et al. Schizophrenia risk from complex variation of complement component 4. Nature. 2016;530:177–83. doi: 10.1038/nature16549.
- Comer AL, Jinadasa T, Sriram B, Phadke RA, Kretsge LN, Nguyen TPH, et al. Increased expression of schizophrenia-associated gene C4 leads to hypoconnectivity of prefrontal cortex and reduced social interaction. PLoS Biol. 2020;18:e3000604. doi: 10.1371/journal.pbio.3000604.
- Yilmaz M, Yalcin E, Presumey J, Aw E, Ma M, Whelan CW, et al. Overexpression of schizophrenia susceptibility factor human complement C4A promotes excessive synaptic loss and behavioral changes in mice. Nat Neurosci. 2020;24:214–24. doi: 10.1038/s41593-020-00763-8.
- Rivas MA, Beaudoin M, Gardet A, Stevens C, Sharma Y, Zhang CK, et al. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011;43:969–78. doi: 10.1038/ng.952.
- Steen VM, Nepal C, Ersland KM, Holdhus R, Nævdal M, Ratvik SM, et al. Neuropsychological deficits in mice depleted of the schizophrenia susceptibility gene CSMD1. PLoS ONE. 2013;8:79501. doi: 10.1371/journal.pone.0079501.
- Baum ML, Wilton DK, Muthukumar A, Fox RG, Carey A, Crotty W, et al. CUB and sushi multiple domains 1 (CSMD1) opposes the complement cascade in neural tissues. bioRxiv. 2020;1:1–56.
- Mongan D, Föcking M, Healy C, Susai SR, Heurich M, Wynne K, et al. Development of proteomic prediction models for transition to psychotic disorder in the clinical high-risk state and psychotic experiences in adolescence. JAMA Psychiatry. 2020;78:77–90. doi: 10.1001/jamapsychiatry.2020.2459.
- Hakobyan S, Boyajyan A, Sim RB. Classical pathway complement activity in schizophrenia. Neurosci Lett. 2005;374:35–37. doi: 10.1016/j.neulet.2004.10.024.
- Mayilyan KR, Arnold JN, Presanis JS, Soghoyan AF, Sim RB. Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. Neurosci Lett. 2006;404:336–41. doi: 10.1016/j.neulet.2006.06.051.
- Merle NS, Church SE, Fremeaux-Bacchi V, Roumenina LT. Complement system part I - molecular mechanisms of activation and regulation. Front Immunol. 2015;6:1–30.
- Wang HBin, Ricklin D, Lambris JD. Complement-activation fragment C4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proc Natl Acad Sci USA. 2017;114:10948–53. doi: 10.1073/pnas.1707364114.
- Bergseth G, Ludviksen JK, Kirschfink M, Giclas PC, Nilsson B, Mollnes TE. An international serum standard for application in assays to detect human complement activation products. Mol Immunol. 2013;56:232–9. doi: 10.1016/j.molimm.2013.05.221.
- Orsini F, De Blasio D, Zangari R, Zanier ER, De Simoni MG. Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front Cell Neurosci. 2014;8:1–19. doi: 10.3389/fncel.2014.00380.
- Pollak TA, Drndarski S, Stone JM, David AS, McGuire P, Abbott NJ. The blood–brain barrier in psychosis. Lancet Psychiatry. 2018;5:79–92. doi: 10.1016/S2215-0366(17)30293-6.
- Loewy RL, Pearson R, Vinogradov S, Bearden CE, Cannon TD. Psychosis risk screening with the Prodromal Questionnaire - Brief Version (PQ-B) Schizophr Res. 2011;129:42–46. doi: 10.1016/j.schres.2011.03.029.
- Nishimura AJ, Erwin PJ, Tilburt JC, Murad MH, McCormick JB. Improving understanding in the research informed consent process: a systematic review of 54 interventions tested in randomized control trials. BMC Med Ethics. 2013;14:28. doi: 10.1186/1472-6939-14-28.
- Sheskin D. Handbook of parametric and nonparametric statistical procedures. Boca Raton: Chapman & Hall/CRC; 2004.
- Zarr J. Biostatistical analysis. Upper Saddle River: Prentice Hall; 1999.
- Kealy J, Greene C, Campbell M. Blood-brain barrier regulation in psychiatric disorders. Neurosci Lett. 2020;726:133664. doi: 10.1016/j.neulet.2018.06.033.
- Kucharska-Mazur J, Tarnowski M, Dołęgowska B, Budkowska M, Pędziwiatr D, Jabłoński M, et al. Novel evidence for enhanced stem cell trafficking in antipsychotic-naïve subjects during their first psychotic episode. J Psychiatr Res. 2014;49:18–24. doi: 10.1016/j.jpsychires.2013.10.016.
- Mongan D, Sabherwal S, Susai SR, Föcking M, Cannon M, Cotter DR. Peripheral complement proteins in schizophrenia: A systematic review and meta-analysis of serological studies. Schizophr Res. 2020;222:58–72. doi: 10.1016/j.schres.2020.05.036.
- Wild G, Watkins J, Ward AM, Hughes P, Hume A, Rowell NR. C4a anaphylotoxin levels as an indicator of disease activity in systemic lupus erythematosus. Clin Exp Immunol. 1990;80:167–70. doi: 10.1111/j.1365-2249.1990.tb05227.x.
- Melbourne JK, Rosen C, Feiner B, Sharma RP. C4A mRNA expression in PBMCs predicts the presence and severity of delusions in schizophrenia and bipolar disorder with psychosis. Schizophr Res. 2018;197:321–7. doi: 10.1016/j.schres.2018.01.018.
- zhang T, Tang Y, Yang X, Wang X, Ding S, Huang K, et al. Expression of GSK3β, PICK1, NEFL, C4, NKCC1 and Synaptophysin in peripheral blood mononuclear cells of the first-episode schizophrenia patients. Asian J Psychiatr. 2021;55:102520. doi: 10.1016/j.ajp.2020.102520.
- Yang Y, Chung EK, Zhou B, Blanchong CA, Yu CY, Füst G, et al. Diversity in intrinsic strengths of the human complement system: serum C4 protein concentrations correlate with C4 gene size and polygenic variations, hemolytic activities, and body mass index. J Immunol. 2003;171:2734–45. doi: 10.4049/jimmunol.171.5.2734.
- Kamitaki N, Sekar A, Handsaker RE, de Rivera H, Tooley K, Morris DL, et al. Complement genes contribute sex-biased vulnerability in diverse disorders. Nature. 2020;582:577–81. doi: 10.1038/s41586-020-2277-x.
- Kilicarslan A, Uysal A, Charles E. Acute phase reactants. Acta Med Cordoba. 2013;2:2–7.
- Vastag M, Skopál J, Kramer J, Kolev K, Vokó Z, Csonka E, et al. Endothelial cells cultured from human brain microvessels produce complement proteins factor H, factor B, C1 inhibitor, and C4. Immunobiology. 1998;199:5–13. doi: 10.1016/S0171-2985(98)80059-4.
- Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21:1696–709. doi: 10.1038/mp.2016.3.
- Lesh TA, Careaga M, Rose DR, McAllister AK, Van de Water J, Carter CS, et al. Cytokine alterations in first-episode schizophrenia and bipolar disorder: relationships to brain structure and symptoms. J Neuroinflammation. 2018;15:1–11. doi: 10.1186/s12974-018-1197-2.
- Isenman DE, Young JR. Covalent binding properties of the C4A and C4B isotypes of the fourth component of human complement on several C1-bearing cell surfaces. J Immunol. 1986;136:2542–25450.
- West EE, Kolev M, Kemper C. Complement and the regulation of T cell responses. Annu Rev Immunol. 2018;36:309–38. doi: 10.1146/annurev-immunol-042617-053245.
- Barnum SR. C4a: an anaphylatoxin in name only. J Innate Immun. 2015;7:333–9. doi: 10.1159/000371423.
- Junge CE, Lee CJ, Hubbard KB, Zhang Z, Olson JJ, Hepler JR, et al. Protease-activated receptor-1 in human brain: Localization and functional expression in astrocytes. Exp Neurol. 2004;188:94–103. doi: 10.1016/j.expneurol.2004.02.018.
- Luo W, Wang Y, Reiser G. Protease-activated receptors in the brain: Receptor expression, activation, and functions in neurodegeneration and neuroprotection. Brain Res Rev. 2007;56:331–45. doi: 10.1016/j.brainresrev.2007.08.002.
- Plitman E, Nakajima S, Fuente-sandoval CDL, Gerretsen P, Chakravarty MM, Kobylianskii J, et al. Glutamate-mediated excitotoxicity in schizophrenia: a review. Eur Neuropsychopharmacol. 2015;24:1591–605. doi: 10.1016/j.euroneuro.2014.07.015.
- Kim YV, Di Cello F, Hillaire CS, Kim KS. Differential Ca2+ signaling by thrombin and protease-activated receptor-1-activating peptide in human brain microvascular endothelial cells. Am J Physiol. 2004;286:C31–42. doi: 10.1152/ajpcell.00157.2003.
- Dragoni S, Papageorgiou A, Araiz C, Greenwood J, Turowski P. Signalling is required for lymphocyte transmigration across brain microvascular. Cells. 2020;9:1–18. doi: 10.3390/cells9122723.
- Xin Y, Hertle E, van der Kallen C, Schalkwijk CG, Stehouwer C, van Greevenbroek M. Complement C3 and C4, but not their regulators or activated products, are associated with incident metabolic syndrome: the CODAM study. Endocrine. 2018;62:617–27. doi: 10.1007/s12020-018-1712-3.
Source: PubMed